
UC research shows people with latent tuberculosis infection are more prone to inflammation
Study examines connection between inflammation, infection and cardiovascular risk
Newly published research from the University of Cincinnati finds that people with latent tuberculosis infection (LTBI) have more inflammation and could be at a higher risk for cardiovascular disease.
The research was published in Open Forum Infectious Diseases, a journal from the Infectious Diseases Society of America.
Roughly 25% of the world population has LTBI, a state where the individual has been exposed to tuberculosis but is not sick from it, says Moises Huaman, MD, of the Division of Infectious Diseases in the Department of Internal Medicine at the UC College of Medicine and corresponding author on the study.
“Developing countries have higher rates of LTBI,” says Huaman. “There are areas in the world where LTBI may affect 50% or so of the population. Here in the United States, the prevalence of LTBI is about 5%, which is still common. It is a global health problem.”
The research team analyzed blood samples from individuals with LTBI in Peru between the ages of 40 and 70.
“We focused on monocytes [a type of white blood cell], and we measured markers associated with immune activation and with cardiovascular disease,” says Geronimo Feria, research associate in the UC Department of Internal Medicine and first author on the study. “We found differences in the expression of monocyte markers that are important not only for infection control but also for atherogenesis, the process of plaque formation [in the arteries] leading to coronary artery heart disease.”
A monocyte is an immune cell that is important for fighting infections like tuberculosis, but also plays a role in cardiovascular health, explains Huaman.
Our study is pioneering in looking at how monocytes may be more pro-inflammatory in people with LTBI. A natural follow-up question would be whether treating LTBI will help treat that inflammation or not.
Moises Huaman, MD
He says another significant element to this research is the role inflammation plays in chronic diseases.
“Anything that leads to an inflammatory state in the body might predispose us to develop chronic diseases. Cardiovascular disease is one of those, along with diabetes, cancer and others,” Huaman says. “Our study is pioneering in looking at how monocytes may be more pro-inflammatory in people with LTBI. A natural follow-up question would be whether treating LTBI will help treat that inflammation or not.”
Huaman says this study and other research in this area highlights that infections in general have a role in cardiovascular disease risk, as evidenced in cases of influenza, HIV and more recently COVID-19.
“I think this is a connection worth exploring because of how common LTBI is,” says Huaman. “The fact that UC is taking a lead on trying to understand how infections affect cardiovascular disease is significant.”
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Medical News Today: Gene mutation may be a key to lung cancer treatment
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.
Pioneering new targeted treatments
June 10, 2022
The University of Cincinnati's Pier Paolo Scaglioni, MD, has received a $1.5 million National Cancer Institute grant to continue research into the roles of the KRAS gene and lipids in lung cancer.
UC research provides valuable comparison of anticoagulant drugs
January 4, 2023
Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis. The research was published in the Annals of Internal Medicine.